Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?

JAMA Netw Open

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, The University of Chicago, Chicago, Illinois.

Published: August 2020


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2020.14184DOI Listing

Publication Analysis

Top Keywords

ready hyperthermic
4
hyperthermic intraperitoneal
4
intraperitoneal chemotherapy
4
chemotherapy upfront
4
upfront treatment
4
treatment ovarian
4
ovarian cancer?
4
ready
1
intraperitoneal
1
chemotherapy
1

Similar Publications

Neoadjuvant therapy, cytoreductive surgery and HIPEC in locally advanced colon cancer: Are we ready for a change in approach?

Cir Esp (Engl Ed)

May 2024

Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Córdoba, Spain; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofia, University of Córdoba, Córdoba, Spain. Electronic address:

View Article and Find Full Text PDF

Background: Surgical subspecialty training aims to meet the needs of practicing surgeons and their communities. This study investigates career preparedness of Complex General Surgical Oncology (CGSO) fellowship graduates, identifies factors associated with practice readiness, and explores potential opportunities to improve the current training model.

Methods: The Society of Surgical Oncology partnered with the National Cancer Institute to conduct a 36-question survey of CGSO fellowship graduates from 2012 to 2022.

View Article and Find Full Text PDF

Introduction: We explored the association between weekend discharge and 30- and 90-d readmission rates in patients undergoing hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis.

Methods: The US HIPEC Collaborative database, comprised of a longitudinal cohort of patients undergoing CRS/HIPEC for peritoneal carcinomatosis at twelve academic institutions between 2000 and 2017, was queried for date of discharge information. Patients were retrospectively divided into weekday and weekend/holiday discharge groups.

View Article and Find Full Text PDF

Clinical effectiveness of hyperthermia treatments, in which tumor tissue is artificially heated to 40-44 °C for 60-90 min, can be hampered by a lack of accurate temperature monitoring. The need for noninvasive temperature monitoring in the head and neck region (H&N) and the potential of MR thermometry prompt us to design an MR compatible hyperthermia applicator: the MRcollar. In this work, we validate the design, numerical model, and MR performance of the MRcollar.

View Article and Find Full Text PDF